What to Look for in COPD Next Year

Slideshow

These brief summaries highlight key developments in COPD and how they are likely to affect patient management in the months and years ahead.

Related Content
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

Sydney Jennings
March 24th 2025
Article

Your daily dose of the clinical news you may have missed.

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose

Sydney Jennings
March 20th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

Patient Care Editorial Staff
March 10th 2025
Article

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Patient Care Editorial Staff
March 6th 2025
Article

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

Fall Risk Near End of Life in COPD / image credit ©Toa555/shutterstock.com

5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life

Grace Halsey
January 30th 2025
Article
FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD

FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD

Sydney Jennings
December 9th 2024
Article

The Prescription Drug User Fee Act date is set for May 7, 2025.

© 2025 MJH Life Sciences

All rights reserved.